...
首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells.
【24h】

Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells.

机译:蛋白质在患有异常T细胞的腹腔疾病患者中特别高表达。

获取原文
获取原文并翻译 | 示例

摘要

An aberrant T cell population is the basis for diagnosis of refractory coeliac disease and determines the risk of enteropathy-associated T cell lymphoma. This disease is serious with a poor survival. Pathogenetic mechanisms sustaining aberrant T cell proliferation remain unknown. Recently, alemtuzumab has been proposed as a promising new approach to treat these patients. Only few single cases have been tested at present; nevertheless, in all the cases a clinical improvement was observed. However, whether intraepithelial lymphocytes have been targeted effectively by alemtuzumab is still debated. This study reports, using two-dimensional difference gel electrophoresis (2D DIGE), hyperexpressed proteins associated specifically with aberrant T cells found in a patient with coeliac disease by comparison of the protein expression of this sample with that of patients with coeliac disease and polyclonal T cells or with control subjects. The data demonstrated a significantly higher expression of IgM, apolipoprotein C-III and Charcot-Leyden crystal proteins in a duodenal biopsy specimen of the patient with clonal T cells compared with that of other patients. These preliminary results allow hypothesizing different clinical effects of alemtuzumab in patients with coeliac disease and aberrant T cell proliferation, because as well as the probable effect on T cells, alemtuzumab could exert its effect by acting on inflammatory associated CD52(+) IgM(+) B cells and eosinophil cells, known to produce IgM and Charcot-Leyden crystal proteins, that we demonstrated to be altered in this patient. The results also emphasize the possible association of apolipoprotein with aberrant T cell proliferation.
机译:T细胞群异常是诊断难治性乳糜泻的基础,并确定了与肠病相关的T细胞淋巴瘤的风险。这种病很严重,存活率很低。维持异常T细胞增殖的发病机制仍然未知。最近,已经提出了alemtuzumab作为治疗这些患者的有希望的新方法。目前只有很少的个案得到测试;然而,在所有情况下都观察到了临床改善。然而,阿仑单抗是否已经有效靶向了上皮内淋巴细胞。这项研究使用二维差异凝胶电泳(2D DIGE),通过将该样品与乳糜泻患者和多克隆T患者的蛋白质表达进行比较,报道了与乳糜泻患者中异常T细胞特异性结合的高表达蛋白质细胞或对照对象。数据表明,与其他患者相比,克隆T细胞患者十二指肠活检标本中IgM,载脂蛋白C-III和夏科特莱登晶体蛋白的表达明显更高。这些初步结果可以假设alemtuzumab对腹腔疾病和异常T细胞增殖的患者具有不同的临床效果,因为alemtuzumab除了可能对T细胞产生作用外,还可以通过作用于炎症相关CD52(+)IgM(+)发挥其作用。 B细胞和嗜酸性粒细胞,已知会产生IgM和夏科特-莱登晶体蛋白,我们证实该患者发生了改变。结果还强调了载脂蛋白与异常T细胞增殖的可能联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号